Literature DB >> 26964539

Plasma exchange response in 34 patients with severe optic neuritis.

Romain Deschamps1, Antoine Gueguen2, Nathalie Parquet3, Samir Saheb4, Francoise Driss5, Malcie Mesnil6, Catherine Vignal7, Jennifer Aboab2, Raphael Depaz2, Olivier Gout2.   

Abstract

Optic neuritis could lead to severe visual impairment despite corticosteroids. Our aim was to evaluate the rate of visual improvement in patients treated with plasma exchange (PLEX) for severe steroid unresponsive optic neuritis and to identify predictive factors of outcome. Thirty-four patients (41 optic nerves damaged) with remaining visual acuity of 0.1 or less despite steroid pulse therapy were treated with PLEX from September 2010 to May 2015. Demographic and clinical neuro-ophthalmic findings, and spectral domain-optical coherence tomography data before PLEX treatment were analyzed. The mean symptom duration before PLEX was 34.6 days (median 28 days; range 6-92 days). After PLEX, the median final visual acuity was 0.8 and in 56 % of cases, final acuity was 0.5 or better. Past history of ipsilateral optic neuritis was associated significantly with poor outcome defined as final acuity less than 0.5. No significant difference in the visual outcome after PLEX was found between multiple sclerosis and neuromyelitis optica. In conclusion, this observational study showed that PLEX as second-line therapy led to a functionally important visual recovery in more than half patients with severe optic neuritis.

Entities:  

Keywords:  Corticosteroids; Multiple sclerosis; Myelin oligodendrocyte glycoprotein; Neuromyelitis optica; Optic neuritis; Plasmapheresis

Mesh:

Substances:

Year:  2016        PMID: 26964539     DOI: 10.1007/s00415-016-8073-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

Review 1.  Plasma exchange for severe optic neuritis: treatment of 10 patients.

Authors:  K Ruprecht; E Klinker; T Dintelmann; P Rieckmann; R Gold
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

Review 2.  Neurologic indications for therapeutic plasma exchange: 2011 update.

Authors:  Kelly Gwathmey; Rasheed A Balogun; Ted Burns
Journal:  J Clin Apher       Date:  2012-04-23       Impact factor: 2.821

3.  Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica.

Authors:  Harold Merle; Stéphane Olindo; Séverine Jeannin; Ruddy Valentino; Hossein Mehdaoui; Florence Cabot; Angélique Donnio; Rabih Hage; Raymond Richer; Didier Smadja; Philippe Cabre
Journal:  Arch Ophthalmol       Date:  2012-07

4.  Should plasma exchange be offered to patients with multiple sclerosis-associated optic neuritis?

Authors:  John H Pula; Christopher C Glisson
Journal:  J Neuroophthalmol       Date:  2015-03       Impact factor: 3.042

5.  Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome.

Authors:  M J Kupersmith; R L Gal; R W Beck; D Xing; N Miller
Journal:  Neurology       Date:  2007-08-07       Impact factor: 9.910

6.  [Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients].

Authors:  S Schilling; R A Linker; F B König; M Koziolek; M Bähr; G A Müller; W Paulus; J Gärtner; W Brück; A Chan; R Gold
Journal:  Nervenarzt       Date:  2006-04       Impact factor: 1.214

7.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

8.  Plasma exchange for severe attacks of CNS demyelination: predictors of response.

Authors:  M Keegan; A A Pineda; R L McClelland; C H Darby; M Rodriguez; B G Weinshenker
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

9.  Beneficial plasma exchange response in central nervous system inflammatory demyelination.

Authors:  Setty M Magaña; B Mark Keegan; Brian G Weinshenker; Bradley J Erickson; Sean J Pittock; Vanda A Lennon; Moses Rodriguez; Kristine Thomsen; Stephen Weigand; Jay Mandrekar; Linda Linbo; Claudia F Lucchinetti
Journal:  Arch Neurol       Date:  2011-03-14

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  13 in total

Review 1.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

2.  Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.

Authors:  Sotaro Mori; Takuji Kurimoto; Kaori Ueda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2018-05-25       Impact factor: 2.447

3.  Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study.

Authors:  Shaoying Tan; Tsz Kin Ng; Quangang Xu; Mo Yang; Yuan Zhuang; Jie Zhao; Huanfen Zhou; Da Teng; Shihui Wei
Journal:  Ther Adv Neurol Disord       Date:  2020-08-21       Impact factor: 6.570

4.  Acute Management of Optic Neuritis: An Evolving Paradigm.

Authors:  Lindsay Horton; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2018-09       Impact factor: 3.042

5.  Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis.

Authors:  Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen
Journal:  Transfus Med Hemother       Date:  2019-11-14       Impact factor: 3.747

Review 6.  Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.

Authors:  Klaus Lehmann-Horn; Silke Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

7.  Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders.

Authors:  B L Kumawat; Reenu Choudhary; C M Sharma; Deepak Jain; Ashwini Hiremath
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

8.  Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses.

Authors:  Steffen Pfeuffer; Leoni Rolfes; Eike Bormann; Cristina Sauerland; Tobias Ruck; Matthias Schilling; Nico Melzer; Marcus Brand; Refik Pul; Christoph Kleinschnitz; Heinz Wiendl; Sven G Meuth
Journal:  J Clin Med       Date:  2019-12-22       Impact factor: 4.241

9.  Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.

Authors:  Johannes Dorst; Tanja Fangerau; Daniela Taranu; Pia Eichele; Jens Dreyhaupt; Sebastian Michels; Joachim Schuster; Albert C Ludolph; Makbule Senel; Hayrettin Tumani
Journal:  EClinicalMedicine       Date:  2019-11-14

10.  Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis.

Authors:  Mark Lipphardt; Manuel Wallbach; Michael J Koziolek
Journal:  J Clin Med       Date:  2020-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.